ADARx Pharmaceuticals, Inc. ADRX
14.96 USD -1.13 (-7.02%)
At closeNov 4, 2026, 4:00 PM EST
14.96 0.00 0.00%
After hours · Nov 4, 4:00 PM ET
14.85 Day range 16.73
14.85 52-week range 23.21
- YTD
- -22.69%
- 1 year
- -22.69%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 34.25 +128.9% upside
Now 14.96
- Target (low)
- 32.00
- Target (mean)
- 34.25
- Target (high)
- 38.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.36348 | -0.53 – -0.25367 | 0.00 | 0.0% | 2.58M | 0.0% | 3 |
| Next quarter | -0.37861 | -0.40 – -0.36363 | 0.00 | 0.0% | 2.58M | 0.0% | 3 |
| Current year | -1.68 | -1.89 – -1.55 | 0.00 | 0.0% | 5.94M | 0.0% | 3 |
| Next year | -1.51 | -1.81 – -1.18 | -1.68 | +9.9% | 39.87M | +570.7% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 20, 2026 | TD Cowen | Initiated | — | Buy |
| Oct 20, 2026 | JP Morgan | Initiated | — | Overweight |
| Oct 20, 2026 | UBS | Initiated | — | Buy |
| Oct 20, 2026 | Morgan Stanley | Initiated | — | Overweight |